补肾化瘀散结方联合西医常规治疗2型糖尿病肾病Ⅳ期临床研究
2018-09-03刘海立连书光
刘海立 连书光
摘要:目的 探討补肾化瘀散结方治疗2型糖尿病肾病Ⅳ期气阴两虚兼血瘀证临床疗效。方法 按照住院顺序号将90例患者随机分为治疗组和对照组各45例。对照组予低蛋白饮食、控制体质量、降糖、降压、降脂、抗凝及改善微循环等西医常规治疗。治疗组在对照组基础上予补肾化瘀散结方,每日1剂,水煎分2次口服。均连续治疗3个月。观察2组治疗前后中医症状积分,血糖、血脂、肾功能、24 h尿蛋白定量(UTP)及血清转化生长因子-β1(TGF-β1)、C反应蛋白(CRP)水平。结果 治疗组临床疗效、中医疗效总有效率分别为80.00%、84.44%,对照组均为62.22%,治疗组优于对照组(P<0.05)。与本组治疗前比较,2组中医症状积分、血糖、血脂、肾功能、UTP及血清TGF-β1、CRP明显改善(P<0.05)。治疗组治疗后中医症状积分、TGF-β1、CRP和UTP优于对照组(P<0.05)。结论 补肾化瘀散结方联合西医常规治疗对2型糖尿病肾病Ⅳ期气阴两虚兼血瘀证患者临床疗效较好,其机制是通过降低TGF-β1、CRP抑制肾间质纤维化,减少尿蛋白排泄,延缓疾病进展。
关键词:糖尿病肾病Ⅳ期;气阴两虚兼血瘀证;补肾化瘀散结方;转化生长因子-β1;C反应蛋白;肾间质纤维化
DOI:10.3969/j.issn.1005-5304.2018.06.009
中图分类号:R259.872 文献标识码:A 文章编号:1005-5304(2018)06-0034-05
Clinical Study on Efficacy of Bushen Huayu Sanjie Prescription Combined with Western Routine Therapy for Treatment of Type 2 Diabetic Nephropathy in Stage Ⅳ
LIU Hai-li, LIAN Shu-guang
Ruzhou Jiren Diabetes Hospital, Ruzhou 467599, China
Abstract: Objective To discuss the clinical efficacy of Bushen Huayu Sanjie Prescription for the treatment of deficiency of both qi and yin and blood stasis in patients with stage Ⅳ of type 2 diabetic nephropathy. Methods Totally 90 patients with stage Ⅳ of type 2 diabetic nephropathy were randomly divided into treatment group and control group, with 45 cases in each group. The control group was given Western routine therapy, such as low-protein diet, control of body mass, hypoglycemic, antihypertensive, lipid-lowering, anticoagulation, and microcirculation, etc. On the basis of control group, treatment group was given Bushen Huayu Sanjie Prescription, one dosage per day, twice a day, orally. The treatment for both groups lasted for three months. TCM symptom scores, blood glucose, blood lipids, renal function, 24-hour urinary total protein (UTP), and serum transforming growth factor-β1 (TGF-β1) and C-reactive protein (CRP) levels before and after treatment in the two groups were observed. Results The total effective rate of clinical efficacy and TCM efficacy of the treatment group were 80.00% and 84.44%, respectively, and the control group was 62.22%. The treatment group was superior to the control group (P<0.05). Compared with before treatment, TCM symptom scores, blood glucose, blood lipids, renal function, UTP, serum CRP, and TGF-β1 were significantly improved in the two groups (P<0.05). The scores of TCM symptoms, TGF-β1, CRP and UTP in the treatment group were better than that in the control group (P<0.05). Conclusion Bushen Huayu Sanjie Prescription combined with Western routine therapy for the treatment of deficiency of both qi and yin and blood stasis in patients with stage Ⅳ of type 2 diabetic nephropathy has good clinical efficacy, which can delay disease progression by reducing TGF-β1 and CRP, inhibiting renal interstitial fibrosis, and decreasing urinary protein excretion.
Keywords: stage Ⅳ of diabetic nephropathy; deficiency of both qi and yin and blood stasis; Bushen Huayu Sanjie Prescription; TGF-β1; CRP; renal interstitial fibrosis
糖尿病肾病(diabetic nephropathy,DN)是糖尿病最严重和最常见的慢性微血管并发症,是导致终末期肾病的首要原因,一旦进入临床蛋白尿期后,进展至终末期肾病的速度约为其他肾病的14倍[1]。我国糖尿病患者对DN知晓率低、治疗率低,DN发病率逐年增高,并呈年轻化趋势[2]。本研究采用自拟补肾化瘀散结方,对2型糖尿病肾病Ⅳ期的气阴两虚兼血瘀证患者进行随机对照研究,观察患者血清转化生长因子-β1(TGF-β1)、C反应蛋白(CRP)及尿蛋白情况,现报道如下。
1 资料与方法
1.1 一般资料
选择2015年7月-2017年6月本院2型糖尿病肾病Ⅳ期气阴两虚兼血瘀证住院患者90例,根据住院顺序号随机分为对照组和治疗组各45例。观察期分住院治疗期和出院治疗期2个时期。……